Table 1.

Clinicopathological features of patients with NSCLC rebiopsied after EGFR TKI resistance acquisition

No. of cases	123
baseline morphology	NSCLC 100%
EGFR TKI
afatinib	55
gefitinib	35
erlotinib	33
median age (range)	68 (40–87)
< 65 years (%)	24
> 65 years (%)	76
sex (%)
male	53
female	70
primary EGFR mutation
EGFR exon 19 deletion	89
EGFR exon 21 p.L858R	33
EGFR exon 19 duplication	1